Half‐dose sorafenib for HCC

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|45|3|279-287

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.45, Iss.3, 2015-03, pp. : 279-287

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Systematic review and meta‐analysis: full‐ vs. half‐dose anti‐microbials in clarithromycin‐based regimens for Helicobacter pylori eradication

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 2, 2015-07 ,pp. : 131-141

John Wiley & Sons Inc

Access to resources Recommend Favorite

Analysis of macular sensitivity using multifocal electroretinogram and microperimetry in central serous chorioretinopathy patients after half‐dose photodynamic therapy

By  

ACTA OPHTHALMOLOGICA, Vol. 94, Iss. S256, 2016-10 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 119-125

Karger

Access to resources Recommend Favorite

A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV‐related HCC treated with sorafenib

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 9, 2015-09 ,pp. : 2147-2154

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 1, 2014-07 ,pp. : 27-35

John Wiley & Sons Inc

Access to resources Recommend Favorite